Nektar TherapeuticsNKTR
NKTR
About: Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Employees: 61
0
Funds holding %
of 7,310 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
620% more call options, than puts
Call options by funds: $885K | Put options by funds: $123K
82% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 17
8% more funds holding
Funds holding: 145 [Q4 2024] → 157 (+12) [Q1 2025]
5.5% less ownership
Funds ownership: 72.04% [Q4 2024] → 66.54% (-5.5%) [Q1 2025]
13% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 48
32% less capital invested
Capital invested by funds: $124M [Q4 2024] → $84.2M (-$39.4M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
21%
upside
Avg. target
$75
203%
upside
High target
$120
385%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Arthur He | 385%upside $120 | Buy Maintained | 24 Jun 2025 |
Jefferies Roger Song | 21%upside $30 | Buy Upgraded | 11 Apr 2025 |
Financial journalist opinion
Based on 19 articles about NKTR published over the past 30 days
Negative
The Motley Fool
2 days ago
Why Nektar Therapeutics Stock Dived by 3% Today
Nektar Therapeutics (NKTR -2.98%) saw its stock price erode on Thursday, following the company's closing of a secondary stock issue. Investors gave the company a thumbs-down on the news by selling out of its shares, leaving it with a 3% loss at the close of trading.
Neutral
PRNewsWire
3 days ago
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO , July 2, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $115 million of shares of its common stock. Nektar sold 4,893,618 shares of common stock in the offering, which includes 638,298 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.
Neutral
PRNewsWire
4 days ago
Nektar Therapeutics Announces Pricing of $100 Million Public Offering
SAN FRANCISCO , July 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering of $100 million of shares of its common stock. Nektar is selling 4,255,320 shares of common stock in the offering.
Neutral
PRNewsWire
5 days ago
Nektar Therapeutics Announces Proposed Public Offering
SAN FRANCISCO , June 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Nektar.
Positive
MarketBeat
5 days ago
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a small number of drug candidates and lacking a means of achieving profitability until one or more of those products make it to market.
Positive
MarketBeat
1 week ago
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
On June 24, Nektar Therapeutics NASDAQ: NKTR stock exploded nearly 157% following news that Rezpeg, the company's experimental treatment for atopic dermatitis (eczema), successfully met its primary and secondary goals in a Phase 2b trial. Nektar joined a wave of micro-cap biotechnology stocks surging after promising clinical trial results.
Positive
Seeking Alpha
1 week ago
Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg
Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg
Positive
The Motley Fool
1 week ago
Why Nektar Therapeutics Stock Was Red-Hot Today
The latest biotech stock to explode in price, Nektar Therapeutics (NKTR 19.10%) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after delivering excellent news from the lab, the company's shares leaped 19% higher on a significant analyst price target change.
Positive
Benzinga
1 week ago
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Nektar Therapeutics NKTR released on Tuesday statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.
Positive
Zacks Investment Research
1 week ago
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.
Charts implemented using Lightweight Charts™